betaherpesvirina
preval
nearli
adult
popul
worldwid
hcmv
infect
associ
viral
persist
latent
form
similar
herpesvirus
reactiv
hcmv
seriou
issu
patient
impair
immun
system
exampl
high
probabl
seriou
coinfect
pneumonia
gastrointestin
diseas
among
other
recipi
donor
organ
bone
marrow
transplant
hivinfect
patient
high
preval
viru
throughout
human
popul
hcmv
common
caus
congenit
viral
infect
newborn
hcmv
abl
penetr
placenta
subsequ
infect
fetu
lead
stillbirth
innat
deform
current
treatment
hcmv
infect
focus
five
fdaapprov
drug
ganciclovir
oral
prodrug
form
valg
anciclovir
foscarnet
cidofovir
prodrug
brincidofovir
unfortun
drug
also
caus
seriou
side
effect
significantli
limit
clinic
util
asid
low
bioavail
drug
also
exhibit
signific
toxic
particular
foscarnet
cidofovir
lead
nephrotox
ganciclovir
inhibit
function
bone
marrow
therebi
lead
thrombocytopenia
granulocytopenia
found
longterm
treatment
hcmv
infect
lead
gener
resist
hcmv
variant
result
urgent
need
find
safer
compound
exhibit
potent
antihcmv
activ
accompani
seriou
side
effect
previous
synthes
seri
w
aryloxi
alkyl
uracil
deriv
contain
n
acetamid
fragment
n
atom
pyrimidin
ring
compound
exhibit
potent
inhibitori
activ
hcmv
hel
cell
cultur
activ
uracil
deriv
bear
five
methylen
group
initi
target
narylamid
prepar
convers
pentyl
uracil
acid
deriv
scheme
method
whose
synthesi
describ
previous
subsequ
treatment
acid
thionyl
chlorid
condens
result
acyl
chlorid
appropri
arylamin
anilin
presenc
pyridin
led
desir
narylamid
yield
second
rout
scheme
method
b
propos
poten
tialli
increas
yield
target
compound
approach
employ
substitut
alkyla
ting
agent
previous
describ
synthesi
sever
rela
ted
compound
method
convers
correspon
ding
anilin
ntrimethylsilyl
deriv
correspond
chloroacetamid
dmf
presenc
excess
potassium
carbon
led
target
compound
yield
br
n
n
h
n
compound
evalu
potenti
inhibitor
broad
set
dna
rna
virus
includ
narylacetamid
gener
procedur
mixtur
mmol
arylamin
hmd
ml
nh
cl
g
reflux
h
homogen
solut
obtain
excess
hmd
remov
reduc
pressur
residu
clear
oil
dissolv
anhydr
ml
solut
chloroacetyl
chlorid
ml
mmol
anhydr
ml
ad
dropwis
stir
mixtur
stir
overnight
room
temperatur
evapor
reduc
pressur
volum
hexan
ml
ad
mixtur
kept
overnight
refri
gerat
result
precipit
filter
recrystal
mixtur
etoachexan
mixtur
carboxyl
acid
deriv
g
mmol
thionyl
chlorid
ml
mmol
anhydr
ml
reflux
exclus
moistur
h
volatil
evapor
reduc
pressur
residu
dissolv
anhydr
ml
result
solut
ad
drop
wise
stir
cool
solut
arylamin
mmol
pyridin
ml
anhydr
ml
stir
addit
h
kept
overnight
room
temperatur
mixtur
wash
aqueou
hcl
ml
water
ml
solvent
evapor
reduc
pressur
crude
product
purifi
flash
chromatographi
elut
chloroethaneetoac
product
recrystal
mixtur
hexan
etoac
method
b
mixtur
pentyl
uracil
g
mmol
k
co
g
mmol
dmf
ml
stir
h
cool
room
temperatur
correspond
acetamid
mmol
ad
stir
continu
h
reaction
mixtur
filter
concentr
reduc
pressur
puri
fie
flash
chromatographi
elut
recrystal
mixtur
hexaneetoac
disappointingli
none
com
pound
seri
show
meaning
antivir
activ
howev
analyz
screen
result
appear
oxygen
atom
acetanilid
fragment
like
make
critic
contribut
antihcmv
activ
thu
new
uracil
acetamid
deriv
seem
promis
class
viral
rep
licat
inhibitor
warrant
structureact
investi
gation
